Report cover image

Japan Kidney Cancer Drugs Market, By Drug Type (Targeted Therapy, Immunotherapy, Cytokine Therapy, Others); By Cancer Type (Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Other Rare Subtypes); By Route o

Publisher BlueWeave Consulting
Published Jun 13, 2025
Length 126 Pages
SKU # BLWC20227848

Description

Japan Kidney Cancer Drugs Market Booming to Surpass USD 370 Million by 2031

Japan Kidney Cancer Drugs Market is flourishing primarily due to the increasing incidence of renal cell carcinoma (RCC) and earlier diagnoses, a robust R&D pipeline focusing on targeted therapies, and a strong healthcare infrastructure with supportive reimbursement policies.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Japan Kidney Cancer Drugs Market size by value at USD 226.15 million in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Japan Kidney Cancer Drugs Market size to boom at a robust CAGR of 7.3% reaching a value of USD 370.33 million by 2031. The growth of Kidney Cancer Drugs Market in Japan is propelled by increasing prevalence of renal cell carcinoma (RCC), with over 21,000 cases reported in 2019, influenced by an aging population and lifestyle factors like smoking. Significant advancements in targeted therapies and immunotherapies, coupled with the rising adoption of personalized medicine, are also propelling market growth; notably, a recent international genomic study identified a specific DNA mutation in nearly 70% of Japanese kidney cancer patients, rarely seen in other populations, highlighting the critical need for tailored therapeutic approaches. The continuous development and approval of innovative drugs, such as immune checkpoint inhibitors and tyrosine kinase inhibitors, are enhancing treatment outcomes and expanding treatment options, especially for advanced-stage RCC, while the growing use of combination therapies and Japan's supportive healthcare infrastructure further contribute to market expansion, anticipating a significant increase in demand for advanced and personalized kidney cancer therapies throughout the forecast period as research continues to uncover new treatment avenues and genetic insights.

Targeted Therapy Segment Holds Largest Market Share
The targeted therapy segment accounts for the largest share of Japan Kidney Cancer Drugs Market by drug type. The segment’s market dominance is attributed to a significant shift toward more precise and effective treatment approaches, stemming from advancements in understanding renal cell carcinoma (RCC) biology. Targeted therapies specifically address molecular pathways and genetic mutations involved in cancer progression, offering enhanced efficacy and a more favorable side effect profile compared to conventional treatments. Key drugs in this segment include tyrosine kinase inhibitors (TKIs), such as sunitinib, sorafenib, and cabozantinib, as well as VEGF inhibitors like bevacizumab, all of which work to impede tumor growth and angiogenesis.

Impact of Escalating Geopolitical Tensions on Japan Kidney Cancer Drugs Market

Intensifying geopolitical tensions could have a multifaceted impact on Japan Kidney Cancer Drugs Market. Disruptions in global supply chains could lead to critical shortages or delays in importing essential raw materials and active pharmaceutical ingredients needed for advanced cancer therapies. Moreover, strained international relations may hinder collaborative research and development efforts, especially in crucial areas like immunotherapies and precision medicine. The imposition of economic sanctions or trade restrictions could also drive-up production costs, ultimately impacting drug affordability and patient access. Consequently, patients in Japan may face limited availability of innovative treatments, potentially compromising care quality and slowing the market's overall growth.

Competitive Landscape
Japan Kidney Cancer Drugs Market is highly fragmented, with numerous players serving the market. Major companies dominating the market include Otsuka Pharmaceutical Co., Ltd, Senju Pharmaceutical Co., Ltd, Kyowa Pharmaceutical Industry Co., Ltd, Janssen Pharmaceuticals K.K., Novartis Pharma K.K., Sun Pharma Japan Limited, Asahi Kasei Pharma Corporation, AbbVie GK, Taisho Pharmaceutical Co., Ltd, and Santen Pharmaceutical Co., Ltd. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in Japan Kidney Cancer Drugs Market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and Japan Kidney Cancer Drugs Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Japan Kidney Cancer Drugs Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

126 Pages
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Japan Kidney Cancer Drugs Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Drivers
3.2.1.1. Rising RCC Incidence & Early Diagnosis
3.2.1.2. Booming R&D & Targeted Therapy Pipeline
3.2.1.3. Strong Healthcare Infrastructure & Reimbursement Support
3.2.2. Restraints
3.2.2.1. High Treatment Cost
3.2.2.2. Limited Pipeline Differentiation
3.2.3. Opportunities
3.2.3.1. Expanding Immunotherapy Combos
3.2.3.2. Personalized Medicine & Biomarker Usage
3.2.4. Challenges
3.2.4.1. Generic Competition & Patent Expiry
3.2.4.2. Regulatory Uncertainties
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Japan Kidney Cancer Drugs Market: Marketing Strategies
5. Japan Kidney Cancer Drugs Market: Pricing Analysis
6. Japan Kidney Cancer Drugs Market Overview
6.1. Market Size & Forecast, 2019–2031
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.1.1. Targeted Therapy
6.2.1.2. Immunotherapy
6.2.1.3. Cytokine Therapy
6.2.1.4. Others
6.2.2. By Cancer Type
6.2.2.1. Clear Cell Renal Cell Carcinoma
6.2.2.2. Papillary Renal Cell Carcinoma
6.2.2.3. Chromophobe Renal Cell Carcinoma
6.2.2.4. Other Rare Subtypes
6.2.3. By Route of Administration
6.2.3.1. Oral
6.2.3.2. Intravenous
7. Competitive Landscape
7.1. List of Key Players and Their Offerings
7.2. Japan Kidney Cancer Drugs Market Share Analysis, 2024
7.2.1. Competitive Benchmarking, By Operating Parameters
7.3. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
8. Impact of Escalating Geopolitical Tensions on Japan Kidney Cancer Drugs Market
9. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
9.1. Otsuka Pharmaceutical Co., Ltd
9.2. Senju Pharmaceutical Co., Ltd
9.3. Kyowa Pharmaceutical Industry Co., Ltd
9.4. Janssen Pharmaceuticals K.K.
9.5. Novartis Pharma K.K.
9.6. Sun Pharma Japan Limited
9.7. Asahi Kasei Pharma Corporation
9.8. AbbVie GK
9.9. Taisho Pharmaceutical Co., Ltd
9.10. Santen Pharmaceutical Co., Ltd
9.11. Other Prominent Players
10. Key Strategic Recommendations
11. Research Methodology
11.1. Qualitative Research
11.1.1. Primary & Secondary Research
11.2. Quantitative Research
11.3. Market Breakdown & Data Triangulation
11.3.1. Secondary Research
11.3.2. Primary Research
11.4. Breakdown of Primary Research Respondents, By Region
11.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.
List of Figures
Figure 1 Japan Retail Pharmacy Segmentation
Figure 2 Japan Kidney Cancer Drugs Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2024
Figure 4 Japan Kidney Cancer Drugs Market Size, By Value (USD Million), 2019–2031
Figure 5 Japan Kidney Cancer Drugs Market Share, By Drug Type, By Value, 2019–2031
Figure 6 Japan Kidney Cancer Drugs Market Share, By Cancer Type, By Value, 2019–2031
Figure 7 Japan Kidney Cancer Drugs Market Share, By Route of Administration, By Value, 2019–2031
Figure 8 Japan Kidney Cancer Drugs Market Share, By Drug Type, By Value, 2019–2031
Figure 9 Japan Kidney Cancer Drugs Market Share, By Cancer Type, By Value, 2019–2031
Figure 10 Japan Kidney Cancer Drugs Market Share, By Route of Administration, By Value, 2019–2031
List of Tables
Table 1 Japan Kidney Cancer Drugs Market Size, By Value (USD Million), 2019–2031
Table 2 Japan Kidney Cancer Drugs Market Share, By Drug Type, By Value, 2019–2031
Table 3 Japan Kidney Cancer Drugs Market Share, By Cancer Type, By Value, 2019–2031
Table 4 Japan Kidney Cancer Drugs Market Share, By Route of Administration, By Value, 2019–2031
Table 5 Japan Kidney Cancer Drugs Market Share, By Drug Type, By Value, 2019–2031
Table 6 Japan Kidney Cancer Drugs Market Share, By Route of Administration, By Value, 2019–2031
Table 7 Otsuka Pharmaceutical Co., Ltd Company Overview
Table 8 Otsuka Pharmaceutical Co., Ltd Financial Overview
Table 9 Senju Pharmaceutical Co., Ltd Company Overview
Table 10 Senju Pharmaceutical Co., Ltd Financial Overview
Table 11 Kyowa Pharmaceutical Industry Co., Ltd Company Overview
Table 12 Kyowa Pharmaceutical Industry Co., Ltd Financial Overview
Table 13 Janssen Pharmaceuticals K.K. Company Overview
Table 14 Janssen Pharmaceuticals K.K. Financial Overview
Table 15 Novartis Pharma K.K. Company Overview
Table 16 Novartis Pharma K.K. Financial Overview
Table 17 Sun Pharma Japan Limited Company Overview
Table 18 Sun Pharma Japan Limited Financial Overview
Table 19 Asahi Kasei Pharma Corporation Company Overview
Table 20 Asahi Kasei Pharma Corporation Financial Overview
Table 21 AbbVie GK Company Overview
Table 22 AbbVie GK Financial Overview
Table 23 Taisho Pharmaceutical Co., Ltd Company Overview
Table 24 Taisho Pharmaceutical Co., Ltd Financial Overview
Table 25 Santen Pharmaceutical Co., Ltd Company Overview
Table 26 Santen Pharmaceutical Co., Ltd Financial Overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us